Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP-101 7-day dose-response crossover study in moderate to severe COPD
2011-001810-32Phase 2Completed
- Sponsor
- Elevation Pharmaceuticals
- Start
- Apr 2011
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of STEMVAC in chronic obstructive pulmonary disease (COPD) (7 arms), sponsored by Elevation Pharmaceuticals. Primary endpoints: Change in trough FEV1 at Day 7, Standardized change in FEV1 AUC 0-24 hours at Day 7 and 2 more. Started Apr 2011; status: completed.
02
Drugs
STEMVAC
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2011-001810-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001810-32.